Literature DB >> 2392101

Effects of MPTP on locomotor activity in mice.

V A Colotla1, E Flores, A Oscos, A Meneses, R Tapia.   

Abstract

Thirty-two mice were randomly assigned to one of 4 groups of 8 animals each: the first received IP saline injections and the other 3 groups received 10, 20 or 30 mg/kg MPTP. Each dose or saline was administered 3 times in 3 consecutive days and locomotor activity was measured during the next 3 days. In addition, the animals were observed in 2 trials in a rotating rod (Rotarod) and a grip test. The 2 highest doses of the drug produced significant increases in locomotor activity. In the other two behavioral tests, the highest dose of MPTP significantly reduced the capability of the animals to remain on the Rotarod on the grid.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2392101     DOI: 10.1016/0892-0362(90)90061-g

Source DB:  PubMed          Journal:  Neurotoxicol Teratol        ISSN: 0892-0362            Impact factor:   3.763


  16 in total

1.  Parkinson's disease-like neuromuscular defects occur in prenyl diphosphate synthase subunit 2 (Pdss2) mutant mice.

Authors:  Carly G K Ziegler; Min Peng; Marni J Falk; Erzsebet Polyak; Elpida Tsika; Harry Ischiropoulos; Dana Bakalar; Julie A Blendy; David L Gasser
Journal:  Mitochondrion       Date:  2011-10-01       Impact factor: 4.160

Review 2.  Genetic targeting of the amphetamine and methylphenidate-sensitive dopamine transporter: on the path to an animal model of attention-deficit hyperactivity disorder.

Authors:  Marc A Mergy; Raajaram Gowrishankar; Gwynne L Davis; Tammy N Jessen; Jane Wright; Gregg D Stanwood; Maureen K Hahn; Randy D Blakely
Journal:  Neurochem Int       Date:  2013-12-08       Impact factor: 3.921

3.  Intrastriatal injection of 5,7-dihydroxytryptamine decreased 5-HT levels in the striatum and suppressed locomotor activity in C57BL/6 mice.

Authors:  L G Chia; D R Ni; F C Cheng; Y P Ho; J S Kuo
Journal:  Neurochem Res       Date:  1999-06       Impact factor: 3.996

4.  Cholinergic and Dopaminergic Alterations in Nigrostriatal Neurons Are Involved in Environmental Enrichment Motor Protection in a Mouse Model of Parkinson's Disease.

Authors:  Willyan Franco Hilario; Alice Laschuk Herlinger; Lorena Bianchine Areal; Lívia Silveira de Moraes; Tamara Andrea Alarcon Ferreira; Tassiane Emanuelle Servane Andrade; Cristina Martins-Silva; Rita Gomes Wanderley Pires
Journal:  J Mol Neurosci       Date:  2016-09-22       Impact factor: 3.444

5.  Strain-dependent recovery of open-field behavior and striatal dopamine deficiency in the mouse MPTP model of Parkinson's disease.

Authors:  R K Schwarting; M Sedelis; K Hofele; G W Auburger; J P Huston
Journal:  Neurotox Res       Date:  1999-09       Impact factor: 3.911

6.  Behavioral, Biochemical and Molecular Characterization of a Parkinson's Disease Mouse Model Using the Neurotoxin 2'-CH3-MPTP: A Novel Approach.

Authors:  Alice Laschuk Herlinger; Agihane Rodrigues Almeida; Sarah Martins Presti-Silva; Evaldo Vitor Pereira; Filipe Andrich; Rita Gomes Wanderley Pires; Cristina Martins-Silva
Journal:  Neuromolecular Med       Date:  2018-01-13       Impact factor: 3.843

Review 7.  Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease.

Authors:  Susan Duty; Peter Jenner
Journal:  Br J Pharmacol       Date:  2011-10       Impact factor: 8.739

8.  Restoration of Noradrenergic Function in Parkinson's Disease Model Mice.

Authors:  Kui Cui; Fan Yang; Turan Tufan; Muhammad U Raza; Yanqiang Zhan; Yan Fan; Fei Zeng; Russell W Brown; Jennifer B Price; Thomas C Jones; Gary W Miller; Meng-Yang Zhu
Journal:  ASN Neuro       Date:  2021 Jan-Dec       Impact factor: 4.146

9.  The I2020T Leucine-rich repeat kinase 2 transgenic mouse exhibits impaired locomotive ability accompanied by dopaminergic neuron abnormalities.

Authors:  Tatsunori Maekawa; Sayuri Mori; Yui Sasaki; Takashi Miyajima; Sadahiro Azuma; Etsuro Ohta; Fumiya Obata
Journal:  Mol Neurodegener       Date:  2012-04-25       Impact factor: 14.195

10.  Gait dynamics in mouse models of Parkinson's disease and Huntington's disease.

Authors:  Ivo Amende; Ajit Kale; Scott McCue; Scott Glazier; James P Morgan; Thomas G Hampton
Journal:  J Neuroeng Rehabil       Date:  2005-07-25       Impact factor: 4.262

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.